Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment
European Journal of Pharmacology · 2023
DOI: 10.1016/j.ejphar.2023.175752 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Aoli Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Ch…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hefei Institutes of Physical Science, Chinese Academy of Sciences.
Abstract (Originalsprache)
Although rat sarcoma viral oncogene homolog (RAS) mutations occur in about 30% of solid tumors, targeting RAS mutations other than KRAS-G12C is still challenging. As an alternative approach, developing inhibitors targeting RAF, the downstream effector of RAS signaling, is currently one of the main strategies for cancer therapy. Selective v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-V600E inhibitors Vemurafenib, Encorafenib, and Dabrafenib have been approved by FDA and received remarkable clinical responses, but these drugs are ineffective against RAS mutant tumors due to limited inhibition on dimerized RAF. In this study, we developed a highly potent pan-RAF inhibitor, IHMT-RAF-128, which exhibited similarly high efficacies in inhibiting both partners of the RAF dimer, and showed potent anti-tumor efficacy against a variety of cancer cells harboring either RAF or RAS mutations, especially Adagrasib and Sotorasib (AMG510) resistant-KRAS-G12C secondary mutations, such as KRAS-G12C-Y96C and KRAS-G12C-H95Q. In addition, IHMT-RAF-128 showed excellent pharmacokinetic profile (PK), and the bioavailability in mice and rats were 63.9%, and 144.1%, respectively. Furthermore, IHMT-RAF-128 exhibited potent anti-tumor efficacy on xenograft mouse tumor models in a dose-dependent manner without any obvious toxicities. Together, these results support further investigation of IHMT-RAF-128 as a potential clinical drug candidate for the treatment of cancer patients with RAF or RAS mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; Hefei Cance…
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China.
- Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, PR China; University…
Förderung
- National Natural Science Foundation of China
- Hefei Institutes of Physical Science, Chinese Academy of Sciences
Zitieren
APA
Wang, A., Liu, J., Li, X., Zou, F., Qi, Z., Qi, S., Liu, Q., Wang, Z., Cao, J., Jiang, Z., Wang, B., Ge, J., Wang, L., Wang, W., Liu, J., & Liu, Q. (2023). Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.175752
Vancouver
Wang A, Liu J, Li X, Zou F, Qi Z, Qi S, et al. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.175752
BibTeX
@article{Wang2023,
author = {Wang, Aoli and Liu, Juan and Li, Xixiang and Zou, Fengming and Qi, Ziping and Qi, Shuang and Liu, Qingwang and Wang, Zuowei and Cao, Jiangyan and Jiang, Zongru and Wang, Beilei and Ge, Juan and Wang, Li and Wang, Wenchao and Liu, Jing and Liu, Qingsong},
title = {Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment},
journal = {European Journal of Pharmacology},
year = {2023},
doi = {10.1016/j.ejphar.2023.175752}
}
EUVIMED